Phase 1 of Stock Market Correction

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article64382.html The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

MGX Minerals Announces Phase Two Development of Silicon Based Anode for High-Energy Lithium-Ion Batteries

MGX Minerals (CSE:XMG) (OTC:MGXMF) reported today that its collaborative research partnership with the University of British Columbia (“UBC”) has completed a comprehensive baseline assessment of metallurgical silicon originating from each of the Company’s three silicon projects in southeastern British Columbia. MGX and UBC are working together to develop next-generation Li-ion batteries capable of quadrupling energy density from current 100 […]

Now For The Intense Phase Of The Silver Bull Market

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article64268.html The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Novus Doses First Patient in Phase 1 Pharmacodynamics Study

Novus Therapeutics (NASDAQ:NVUS) has officially dosed the first patient in its phase 1 pharmacodynamics clinical trial to treat otitis media, which are inflammatory diseases of the middle ear, the company said on Monday (February 11). The study, called OP0201-C-001, is evaluating the company’s lead product candidate OP0201 for safety, tolerability and Eustachian tube (ET) function after […]

CannTrust Secures Phase 3 Expansion in Pelham

A dispute over a bylaw ruling in Pelham, Ontario with a Canadian licensed producer (LP) gets resolved, leading to a stock jump for the company. After a ruling had left CannTrust Holdings (TSX:TRST) scrambling to find a solution for its expansion plans in Pelham, the cannabis firm announced on Tuesday (January 22) it had obtained […]

This is the Year for NurOwn’s Stem Cell Phase 3 ALS Development

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is involved in all stages of autologous cell therapy development for neurodegenerative diseases with a Phase 3 trial currently underway for ALS. Dr. Ralph Kern, chief medical and chief operating officer at Brainstorm explains his company’s technology, NurOwn, takes patients own autologous stem cells and converts them into differentiated cells. The […]

Vaccinex Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503

Vaccinex (Nasdaq:VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth Evans, Ph.D., provided a podium presentation at the Cambridge Healthtech Institute’s 18th Annual PepTalk on the company’s […]

Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Kalytera Therapeutics, Inc. (TSXV:KALY and OTCQB:KALTF) (the “Company” or “Kalytera”) today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. GVHD occurs when the […]

Berkwood Drills 90m Of Graphite During Ongoing Phase 4 Drilling And Provides An Overview Of Mise-A-La-Masse Geophysical Results At The Lac Gueret South Graphite Project

Berkwood Resources Ltd. (TSXV:BKR, FSE:BK2, WKN:A110N3) (“Berkwood” or the “Company”) is pleased to announce that drilling at its Phase 4 definition drilling program on Zone 1 at the Company’s 100% owned Lac Gueret South Project is continuing. The Program is designed to extend eastward, and to infill drill portions of, the current mineralization model: to date […]

Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient has been dosed in a Phase 1/1b clinical trial of APVO436, a novel anti-CD123 by anti-CD3 bispecific antibody based on Aptevo’s ADAPTIR technology, which is being developed for the treatment of patients with Acute Myeloid […]

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial

Kiniksa Pharmaceuticals (Nasdaq: KNSA) a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling, in subjects with symptomatic recurrent pericarditis. The data show reductions in both […]

Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced an update of the ProSTAR study, its ongoing Phase 1b/2 clinical trial of CPI-1205 in patients with metastatic castration-resistant prostate cancer (mCRPC). As quoted in the press release: The ProSTAR study is evaluating CPI-1205, Constellation’s potent and […]

Phase Two of Ethereum (ETH) is Coming Soon, Says Joe Lubin

Ethereum phase two: Co-founder of Ethereum (ETH), Joseph Lubin, just made a big announcement about the world’s second largest blockchain ecosystem. He spoke at the Rise conference yesterday in Hong Kong and revealed that the first layer of the Ethereum ecosystem is now complete and phase two should be finalized sometime this year. Lubin states that […]

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, today announced that the Company has received approval from the Spanish Agency for Medicinal Products and Medical Devices (AEMPS), to initiate its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of ANAVEX®2-73 for […]